Long non-coding RNAs drive metastatic progression in melanoma (review)

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2181-2186

  Akhbari, Pouria ^a   Whitehouse, Adrian ^b,c   Boyne, James R ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b Faculty of Biological Sciences   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Long non coding RNA; Melanoma; Metastasis

Indexed keywords

LONG UNTRANSLATED RNA; TUMOR PROTEIN;

BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MELANOMA; METASTASIS; PATHOLOGY; PROGNOSIS;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; RNA, LONG NONCODING;

EID: 84907701046     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2691     Document Type: Review

References (73)

1. Weyers W: The 'epidemic' of melanoma between under- and overdiagnosis. J Cutan Pathol 39:9-16, 2012.
2. Lomas J, Martin-Duque P, Pons M and Quintanilla M: The genetics of malignant melanoma. Front Biosci 13:5071-5093, 2008.
3. Hill VK, Gartner JJ, Samuels Y and Goldstein AM: The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 14:257-279, 2013.
4. Bougnoux AC and Solassol J: The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma. Clin Biochem 46:518-523, 2013.
5. ENCO DE Project Consortium: An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-74, 2012.
6. Clark MB, Amaral PP, Schlesinger FJ, et al: The reality of pervasive transcription. PLoS Biol 9: e1000625; discussion e1001102, 2011.
7. Crick F: Central dogma of molecular biology. Nature 227:561-563, 1970.
8. Graur D, Zheng Y, Price N, Azevedo RB, Zufall RA and Elhaik E: On the immortality of television sets: 'function' in the human genome according to the evolution-free gospel of ENCO DE. Genome Biol Evol 5:578-590, 2013.
9. Doolittle WF: Is junk DNA bunk? A critique of ENCO DE. Proc Natl Acad Sci USA 110:5294-5300, 2013.
10. Tessitore A, Cicciarelli G, Del Vecchio F, et al: microRNAs in the DNA damage/repair network and cancer. Int J Genomics 2014:820248, 2014.
11. Condorelli G, Latronico MV and Cavarretta E: microRNAs in cardiovascular diseases: current knowledge and the road ahead. J. Am Coll Cardiol 63:2177-2187, 2014.
12. Yin KJ, Hamblin M and Chen YE: Non-coding RNA s in cerebral endothelial pathophysiology: emerging roles in stroke. Neurochem Int: April 3, 2014 (Epub ahead of print).
13. Lukiw WJ and Alexandrov PN: Regulation of complement factor H (CF H) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol Neurobiol 46:11-19, 2012.
14. Filatova EV, Alieva AKh, Shadrina MI and Slominsky PA: MicroRNAs: possible role in pathogenesis of Parkinson's disease. Biochemistry (Mosc) 77:813-819, 2012.
15. Voller D, Ott C and Bosserhoff A: MicroRNA s in malignant melanoma. Clin Biochem 46:909-917, 2013.
16. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V and Kashani-Sabet M: miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 286:16606-16614, 2011.
17. Braig S, Mueller DW, Rothhammer T and Bosserhoff AK: MicroRNA miR-196a is a central regulator of HOX-B 7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci 67:3535-3548, 2010.
18. Mueller DW and Bosserhoff AK: MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C 8 expression. Int J Cancer 129:1064-1074, 2011.
19. Levati L, Pagani E, Romani S, et al: MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 24:538-550, 2011.
20. Deng Y, Deng H, Bi F, et al: MicroRNA-137 targets carboxylterminal binding protein 1 in melanoma cell lines. Int J Biol Sci 7:133-137, 2011.
21. Bemis LT, Chen R, Amato CM, et al: MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 68:1362-1368, 2008.
22. Segura MF, Hanniford D, Menendez S, et al: Aberrant miR-182 expression promotes melanoma metastasis by repressing FO XO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106:1814-1819, 2009.
23. Haflidadottir BS, Bergsteinsdottir K, Praetorius C and Steingrimsson E: miR-148 regulates Mitf in melanoma cells. PLoS One 5: e11574, 2010.
24. Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor-suppressive PTEN ceRNA s in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-395, 2011.
25. Volders PJ, Helsens K, Wang X, et al: LNC ipedia: a database for annotated human lncRNA transcript sequences and structures. Nucleic Acids Res 41: D246-D251, 2013.
26. Brockdorff N, Ashworth A, Kay GF, et al: The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell 71:515-526, 1992.
27. Rinn JL, Kertesz M, Wang JK, et al: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNA s. Cell 129:1311-1323, 2007.
28. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009.
29. Dickson PV and Gershenwald JE: Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 20:1-17, 2011.
30. Zhang H, Chen Z, Wang X, Huang Z, He Z and Chen Y: Long non-coding RNA: a new player in cancer. J Hematol Oncol 6:37, 2013.
31. Cheetham SW, Gruhl F, Mattick JS and Dinger ME: Long noncoding RNA s and the genetics of cancer. Br J Cancer 108:2419-2425, 2013.
32. Tsai MC, Manor O, Wan Y, et al: Long noncoding RNA as modular scaffold of histone modification complexes. Science 329:689-693, 2010.
33. Wu ZH, Wang XL, Tang HM, et al: Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep 32:395-402, 2014.
34. Sorensen KP, Thomassen M, Tan Q, et al: Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 142:529-536, 2013.
35. Qiu JJ, Lin YY, Ye LC, et al: Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol 134:121-128, 2014.
36. Niinuma T, Suzuki H, Nojima M, et al: Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 72:1126-1136, 2012.
37. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX and De W: The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer 13:464, 2013.
38. Kogo R, Shimamura T, Mimori K, et al: Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 71:6320-6326, 2011.
39. Kim K, Jutooru I, Chadalapaka G, et al: HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32:1616-1625, 2013.
40. Geng YJ, Xie SL, Li Q, Ma J and Wang GY: Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 39:2119-2128, 2011.
41. Ding C, Cheng S, Yang Z, et al: Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. Int J Mol Sci 15:4060-4076, 2014.
42. Cui L, Xie XY, Wang H, Chen XL, Liu SL and Hu LN: Expression of long non-coding RNA HOTAIR mRNA in ovarian cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 44:57-59, 2013 (In Chinese).
43. Gupta RA, Shah N, Wang KC, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071-1076, 2010.
44. Tang L, Zhang W, Su B and Yu B: Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int 2013:251098, 2013.
45. Watanabe H: Extracellular matrix..regulation of cancer invasion and metastasis. Gan To Kagaku Ryoho 37:2058-2061, 2010 (In Japanese).
46. Labrie M and St-Pierre Y: Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci 70:3109-3124, 2013.
47. Frank A, David V, Aurelie TR, Florent G, William H and Philippe B: Regulation of MMPs during melanoma progression: from genetic to epigenetic. Anticancer Agents Med Chem 12:773-782, 2012.
48. Khaitan D, Dinger ME, Mazar J, et al: The melanoma-upregulated long noncoding RNA SPRY 4-IT 1 modulates apoptosis and invasion. Cancer Res 71:3852-3862, 2011.
49. Reuter JS and Mathews DH: RNA structure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics 11:129, 2010.
50. Hofacker IL: RNA secondary structure analysis using the Vienna RNA package. Curr Protoc Bioinformatics Chapter 12: Unit 12-2, 2004.
51. Rigoutsos I, Huynh T, Miranda K, Tsirigos A, McHardy A and Platt D: Short blocks from the noncoding parts of the human genome have instances within nearly all known genes and relate to biological processes. Proc Natl Acad Sci USA 103:6605-6610, 2006.
52. Zou Y, Jiang Z, Yu X, et al: Upregulation of long noncoding RNA SPRY 4-IT 1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS One 8: e79598, 2013.
53. Xie HW, Wu QQ, Zhu B, et al: Long noncoding RNA SPRY 4-IT 1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol: May 9, 2014 (Epub ahead of print).
54. Guil S and Esteller M: Cis-acting noncoding RNA s: friends and foes. Nat Struct Mol Biol 19:1068-1075, 2012.
55. Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA and Winn RA: Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res 8:833-843, 2010.
56. Leeksma OC, Van Achterberg TA, Tsumura Y, et al: Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem 269:2546-2556, 2002.
57. Russo A, Ficili B, Candido S, et al: Emerging targeted therapies for melanoma treatment (review). Int J Oncol 45:516-524, 2014.
58. Wu CF, Tan GH, Ma CC and Li L: The non-coding RNA llme23 drives the malignant property of human melanoma cells. J Genet Genomics 40:179-188, 2013.
59. Patton JG, Porro EB, Galceran J, Tempst P and Nadal-Ginard B: Cloning and characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev 7:393-406, 1993.
60. Song X, Sun Y and Garen A: Roles of PSF protein and VL 30 RNA in reversible gene regulation. Proc Natl Acad Sci USA. 102:12189-12193, 2005.
61. Wang G, Cui Y, Zhang G, Garen A and Song X: Regulation of proto-oncogene transcription, cell proliferation, and tumorigenesis in mice by PSF protein and a VL 30 noncoding RNA. Proc Natl Acad Sci USA 106:16794-16798, 2009.
62. Song X, Wang B, Bromberg M, Hu Z, Konigsberg W and Garen A: Retroviral-mediated transmission of a mouse VL 30 RNA to human melanoma cells promotes metastasis in an immunodeficient mouse model. Proc Natl Acad Sci USA 99:6269-6273, 2002.
63. Tsukahara T, Matsuda Y and Haniu H: PSF knockdown enhances apoptosis via downregulation of LC 3B in human colon cancer cells. Biomed Res Int 2013:204973, 2013.
64. Ren S, She M, Li M, et al: The RNA/DNA-binding protein PSF relocates to cell membrane and contributes cells' sensitivity to antitumor drug, doxorubicin. Cytometry A 85:231-241, 2014.
65. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002.
66. Flaherty KT and McArthur G: BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116:4902-4913, 2010.
67. Bamford S, Dawson E, Forbes S, et al: The CO SMIC. (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355-358, 2004.
68. Jarkowski A 3rd and Khushalani NI: BRAF and beyond: tailoring strategies for the individual melanoma patient. J Carcinog 13:1, 2014.
69. Flockhart RJ, Webster DE, Qu K, et al: BRAFV 600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res 22:1006-1014, 2012.
70. Berger MF, Levin JZ, Vijayendran K, et al: Integrative analysis of the melanoma transcriptome. Genome Res 20:413-427, 2010.
71. Kong L, Zhang Y, Ye ZQ, et al: CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res 35: W345-W349, 2007.
72. Kawada K, Sonoshita M, Sakashita H, et al: Pivotal role of CXCR 3 in melanoma cell metastasis to lymph nodes. Cancer Res 64:4010-4017, 2004.
73. Fu Y, Dominissini D, Rechavi G and He C: Gene expression regulation mediated through reversible m6A RNA methylation. Nat Rev Genet 15:293-306, 2014.